HGH Fragment 176-191 vs Survodutide
A side-by-side research comparison of HGH Fragment 176-191 and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | HGH Fragment 176-191 | Survodutide |
|---|---|---|
| Full name | Human Growth Hormone Fragment 176-191 | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | Phase 3 Clinical Trial |
| Mechanism | Mimics lipolytic action of HGH by stimulating beta-3 adrenergic receptors on adipocytes, increasing cyclic AMP and hormone-sensitive lipase activity. Does not affect IGF-1. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 1,817 Da | 4,500 Da (approximate) |
| Half-life | 3-4 hours | 5-7 days |
| Bioavailability | High (SubQ) | High (SubQ) |
| Typical dose | 250-500 mcg | 0.6-6.0 mg |
| Frequency | 1-2x daily | Once weekly |
| Route | Subcutaneous | Subcutaneous |
HGH Fragment 176-191 reported benefits
- Targeted fat loss
- No IGF-1 elevation
- No glucose impairment
- No bone/organ growth effects
- Improved body composition
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.